 |
 |
To Jim Cordy: A hearty "amen" to your remarks about research funding. Now it seems I have a related question which perhaps you can illuminate: I see three basic sources of PD research funding: (1) Government (2) Corporate, usually prospective or hopeful drug makers (3) Private, institutions or fundraisers How do you ensure that the three sources don't lose effectiveness by overlapping? That is, what class of research should be supported by what kind of source? For example, I should not expect government or private sources to support development of another dopamine agonist; or should they? Are distinctions already made in this? Cheers, Joe J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks CA 91403